Shield Therapeutics plc

DB:1JS Stock Report

Market Cap: €76.3m

Shield Therapeutics Valuation

Is 1JS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of 1JS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: 1JS (€0.07) is trading below our estimate of future cash flow value (€0.32)

Significantly Below Future Cash Flow Value: 1JS is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1JS?

Key metric: As 1JS is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 1JS. This is calculated by dividing 1JS's market cap by their current revenue.
What is 1JS's PS Ratio?
PS Ratio1.8x
SalesUS$49.70m
Market CapUS$87.08m

Price to Sales Ratio vs Peers

How does 1JS's PS Ratio compare to its peers?

The above table shows the PS ratio for 1JS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.8x
HIGH Cantourage Group
19x27.93%€74.1m
93M1 MPH Health Care
2.4x-2.90%€124.2m
0K30 TFF Pharmaceuticals
8.8xn/a€9.7m
B8FK Biofrontera
1.1xn/a€14.6m
1JS Shield Therapeutics
1.8x21.98%€65.2m

Price-To-Sales vs Peers: 1JS is good value based on its Price-To-Sales Ratio (1.8x) compared to the peer average (7.8x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does 1JS's PS Ratio compare vs other companies in the DE Pharmaceuticals Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
NV5 AcuCort
0.3xn/aUS$239.71m
VP2 Valeo Pharma
0.01x20.92%US$520.38k
L7R Lipidor
0.2xn/aUS$92.68k
7IZ Ziccum
0.06xn/aUS$30.58k
No more companies available in this PS range
1JS 1.8xIndustry Avg. 4.0xNo. of Companies4PS01.22.43.64.86+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 1JS is good value based on its Price-To-Sales Ratio (1.8x) compared to the European Pharmaceuticals industry average (4x).

Price to Sales Ratio vs Fair Ratio

What is 1JS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1JS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.8x
Fair PS Ratio1.7x

Price-To-Sales vs Fair Ratio: 1JS is expensive based on its Price-To-Sales Ratio (1.8x) compared to the estimated Fair Price-To-Sales Ratio (1.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1JS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.068
€0.19
+183.32%
27.86%€0.27€0.14n/a3
Jul ’27€0.068
€0.19
+183.32%
27.86%€0.27€0.14n/a3
Jun ’27€0.062
€0.20
+223.79%
23.24%€0.27€0.16n/a3
May ’27€0.091
€0.20
+119.40%
23.24%€0.27€0.16n/a3
Apr ’27€0.096
€0.20
+106.76%
23.24%€0.26€0.16n/a3
Mar ’27€0.10
€0.20
+89.90%
23.24%€0.26€0.16n/a3
Feb ’27€0.13
€0.20
+56.24%
23.24%€0.27€0.16n/a3
Jan ’27€0.10
€0.18
+74.41%
33.46%€0.26€0.11n/a3
Dec ’26€0.12
€0.18
+54.94%
33.46%€0.26€0.11n/a3
Nov ’26€0.071
€0.18
+158.47%
33.46%€0.26€0.11n/a3
Oct ’26€0.067
€0.16
+135.46%
59.22%€0.26€0.037n/a3
Sep ’26€0.077
€0.16
+106.98%
59.22%€0.27€0.037n/a3
Aug ’26€0.052
€0.16
+204.68%
59.22%€0.27€0.037n/a3
Jul ’26€0.032
€0.16
+404.49%
59.22%€0.27€0.038€0.0683
Jun ’26€0.027
€0.16
+497.92%
59.22%€0.27€0.038€0.0623
May ’26€0.025
€0.16
+545.75%
59.22%€0.27€0.038€0.0913
Apr ’26€0.034
€0.17
+385.78%
56.52%€0.27€0.045€0.0963
Mar ’26€0.038
€0.17
+341.77%
56.52%€0.28€0.046€0.103
Feb ’26€0.036
€0.20
+453.53%
79.10%€0.36€0.042€0.132
Jan ’26€0.029
€0.20
+608.90%
79.10%€0.36€0.042€0.102
Dec ’25€0.033
€0.20
+519.30%
79.10%€0.36€0.042€0.122
Nov ’25€0.034
€0.20
+492.59%
79.10%€0.36€0.042€0.0712
Oct ’25€0.053
€0.20
+274.59%
79.10%€0.36€0.042€0.0672
Sep ’25€0.051
€0.19
+273.51%
87.50%€0.36€0.024€0.0772
Aug ’25€0.036
€0.19
+429.14%
87.50%€0.36€0.024€0.0522
Jul ’25€0.021
€0.19
+766.15%
87.50%€0.35€0.023€0.0322
€0.19
Fair Value
63.4% undervalued intrinsic discount
3
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/07 04:15
End of Day Share Price 2026/07/07 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Shield Therapeutics plc is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Howard MillerCanaccord Genuity
Mark BrewerCavendish
Michael MitchellCavendish